Francine Foss, MD
Basic profileProfessor of Medicine (Hematology) and of Dermatology; Director, Multidisciplinary T cell Lymphoma Program · Yale Cancer Center
Francine Foss is Professor of Medicine (Hematology) and of Dermatology; Director, Multidisciplinary T cell Lymphoma Program at Yale Cancer Center. OpenAlex indexes 521 publications with 17,103 citations (h-index 49); ClinicalTrials.gov lists 10 registered studies matched to this name.
Overview
Updated 20 Oct 2026
Francine Foss, MD, is Professor of Medicine (Hematology) and of Dermatology at Yale School of Medicine / Yale Cancer Center. The public record shows 293 publications with 10,190 citations (h-index 49), centered on Lymphoma Diagnosis and Treatment, Cutaneous lymphoproliferative disorders research, T-cell and B-cell Immunology. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 15 companies.
- Most recent indexed publication: 2026 · Hematology reports
- Top research focus: Lymphoma Diagnosis and Treatment
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 20 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 117.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Howard Ave
Yale Physicians Building
New Haven, CT 06519-1369
Telephone
203-785-2140Registry record last updated 11 Jan 2013 · collected 28 Jul 2026.
Clinical trials
Updated 20 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Sponsor: Corvus Pharmaceuticals, Inc.
InvestigatorPhase 3RecruitingNCT06561048 - Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Sponsor: Associazione Angela Serra per la ricerca sul cancro
- Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma
Sponsor: Yale University
Industry payments
Updated 20 Oct 2026
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- KYOWA KIRIN, INC.Program year202515 payments$16,549openpaymentsdata.cms.gov ↗
- Acrotech Biopharma Inc.Program year20257 payments
- Secura Bio, Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
28.2%Corticosteroid10.5%Prednisone100%Part D≥22 patientsPotassium supplement6.9%Potassium Chloride100%Part D<11 patients+ 3 more classes in this area
Dermatology
22.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor16.7%Acyclovir100%Part D≥25 patientsCorticosteroid5.9%Triamcinolone Acetonide100%Part D≥12 patientsCancer & immunology
17.7%Retinoid7.2%Bexarotene100%Part D<11 patientsFolate Analog Metabolic Inhibitor4.1%Methotrexate100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Congress activity
Updated 20 Oct 2026
44 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Investigating practice patterns in bone marrow biopsies for cutaneous T-cell lymphoma: A multicenter clinician survey.
ASCO Annual Meeting
ASCO2025Co-author - Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 20 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.
The Journal of dermatological treatment
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 20 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 20 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
newswise.com/users/expert/10052665
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newswise.com ↗ - YouTube
yalecancercenter.org/media-player/meet-dr-francine-foss
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalecancercenter.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 20 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Editorial & leadership roles
journal and society appointments- Co-founder and co-chairman
T CELL Forum
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Co-founder and President
United States Cutaneous Lymphoma Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Director
International T-cell Project (T cell lymphoma registry)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- Committee Member
Center for International Blood and Marrow Transplant Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Secondary affiliations
appointments beyond the home institution- Professor of Dermatology (secondary appointment)
Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Co-director
Cutaneous Lymphoma Program, Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalemedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ian Krop, MD
Yale Cancer Center
Harriet Kluger, MD
Yale Cancer Center
Stephanie Halene, MD
Yale Cancer Center
John Kunstman, MD
Yale Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”